Monoclonal antibody targeting complement C9 binding domain of Trichinella spiralis paramyosin impairs the viability of Trichinella infective larvae in the presence of complement

Particle and Fibre Toxicology

Xinping Zhu¹  Ran Sun¹  Yuan Gu¹  Jing Yang¹  Xi Zhao¹  Yuwan Hao¹ 

[1] Department of Parasitology, School of Basic Medical Sciences, Capital Medical University, Beijing, China

关键词: Monoclonal antibody;    Paramyosin;    Immune evasion;    Trichinella spiralis;   

Others  :  1183566
DOI  :  10.1186/1756-3305-7-313

 received in 2014-05-27, accepted in 2014-07-01,  发布年份 2014

【 摘 要 】

Background

Trichinella spiralis expresses paramyosin (Ts-Pmy) not only as a structural protein but also as an immunomodulator that inhibits host complement as a survival strategy. Previous studies demonstrated that Ts-Pmy bound to complement components C8 and C9 and inhibited the polymerization of C9 during the formation of the membrane attack complex (MAC). The C9 binding domain of Ts-Pmy was identified within 14 amino acid residues at the C-terminus of Ts-Pmy. The production of a monoclonal antibody that specifically targets the C9 binding site is necessary for further studies of Ts-Pmy function and may be used as a therapeutic agent for T. spiralis infection.

Methods

In this study, a monoclonal antibody against the complement C9 binding domain of Ts-Pmy (mAb 9G3) was produced using hybridoma technology. The binding activity of the mAb produced for recombinant or native Ts-Pmy and the blockade of Ts-Pmy binding to C9 by the mAb were assessed by Western blot analysis. The effect of the mAb on the viability of T. spiralis was observed by co-incubation of T. spiralis with mAb 9G3 in the presence of complement in vitro and by passive transfer of the mAb into naive mice following T. spiralis larval challenge.

Results

mAb 9G3 was successfully produced against the C9 binding domain of Ts-Pmy and bound specifically not only to recombinant Ts-Pmy but also to native Ts-Pmy expressed in different stages of T. spiralis, including adult worms, newborn larvae and muscle larvae. The binding of mAb 9G3 to Ts-Pmy efficiently blocked the binding of Ts-Pmy to human complement C9, resulting in a significant increase in the complement-mediated killing of newborn larvae in vitro and reduced infectivity of T. spiralis larvae in mice passively transferred with the mAb.

Conclusions

mAb 9G3 is a specific antibody that binds to the C9 binding domain of Ts-Pmy and interferes with Ts-Pmy’s complement-binding activity. Therefore, this mAb is a protective antibody that has potential as a preventive and therapeutic agent for T. spiralis infection.

【 授权许可】

   
2014 Hao et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Gottstein B, Pozio E, Nockler K: Epidemiology, diagnosis, treatment, and control of trichinellosis. Clin Microbiol Rev 2009, 22(1):127-145.
• [2]Dupouy-Camet J: Trichinellosis: a worldwide zoonosis. Vet Parasitol 2000, 93(3–4):191-200.
• [3]Dupouy-Camet J: Presidential address of ICT12 Conference: “Trichinella and trichinellosis–a never ending story”. Vet Parasitol 2009, 159(3–4):194-196.
• [4]Zhang YL, Wang ZQ, Li LG, Cui J: Molecular characterization of Trichinella spiralis aminopeptidase and its potential as a novel vaccine candidate antigen against trichinellosis in BALB/c mice. Parasit Vectors 2013, 6(1):246. BioMed Central Full Text
• [5]Zumaquero-Rios JL, Garcia-Juarez J, De-la-Rosa-Arana JL, Marcet R, Sarracent-Perez J: Trichinella spiralis: monoclonal antibody against the muscular larvae for the detection of circulating and fecal antigens in experimentally infected rats. Exp Parasitol 2012, 132(4):444-449.
• [6]Lambris JD, Ricklin D, Geisbrecht BV: Complement evasion by human pathogens. Nat Rev Microbiol 2008, 6(2):132-142.
• [7]Bruschi F: The immune response to the parasitic nematode Trichinella and the ways to escape it. From experimental studies to implications for human infection. Curr Drug Targets Immune Endocr Metabol Disord 2002, 2(3):269-280.
• [8]Hong Y, Kim CW, Ghebrehiwet B: Trichinella spiralis: activation of complement by infective larvae, adults, and newborn larvae. Exp Parasitol 1992, 74(3):290-299.
• [9]Kennedy MW, Kuo YM: The surfaces of the parasitic nematodes Trichinella spiralis and Toxocara canis differ in the binding of post-C3 components of human complement by the alternative pathway. Parasite Immunol 1988, 10(4):459-463.
• [10]Nareaho A, Saari S, Meri S, Sukura A: Complement membrane attack complex formation and infectivity of Trichinella spiralis and T. nativa in rats. Vet Parasitol 2009, 159(3–4):263-267.
• [11]Elfvin M, Levine RJ, Dewey MM: Paramyosin in invertebrate muscles. I. Identification and localization. J Cell Biol 1976, 71(1):261-272.
• [12]Lanar DE, Pearce EJ, James SL, Sher A: Identification of paramyosin as schistosome antigen recognized by intradermally vaccinated mice. Science 1986, 234(4776):593-596.
• [13]Nanduri J, Kazura JW: Paramyosin-enhanced clearance of Brugia malayi microfilaremia in mice. J Immunol 1989, 143(10):3359-3363.
• [14]Muhlschlegel F, Sygulla L, Frosch P, Massetti P, Frosch M: Paramyosin of Echinococcus granulosus: cDNA sequence and characterization of a tegumental antigen. Parasitol Res 1993, 79(8):660-666.
• [15]Ferrer E, Moyano E, Benitez L, Gonzalez LM, Bryce D, Foster-Cuevas M, Davila I, Cortez MM, Harrison LJ, Parkhouse RM, Garate T: Cloning and characterization of Taenia saginata paramyosin cDNA. Parasitol Res 2003, 91(1):60-67.
• [16]Yang J, Yang Y, Gu Y, Li Q, Wei J, Wang S, Boireau P, Zhu X: Identification and characterization of a full-length cDNA encoding paramyosin of Trichinella spiralis. Biochem Biophys Res Commun 2008, 365(3):528-533.
• [17]Laclette JP, Shoemaker CB, Richter D, Arcos L, Pante N, Cohen C, Bing D, Nicholson-Weller A: Paramyosin inhibits complement C1. J Immunol 1992, 148(1):124-128.
• [18]Deng J, Gold D, LoVerde PT, Fishelson Z: Mapping of the complement C9 binding domain in paramyosin of the blood fluke Schistosoma mansoni. Int J Parasitol 2007, 37(1):67-75.
• [19]Deng J, Gold D, LoVerde PT, Fishelson Z: Inhibition of the complement membrane attack complex by Schistosoma mansoni paramyosin. Infect Immun 2003, 71(11):6402-6410.
• [20]Zhang Z, Yang J, Wei J, Yang Y, Chen X, Zhao X, Gu Y, Cui S, Zhu X: Trichinella spiralis paramyosin binds to C8 and C9 and protects the tissue-dwelling nematode from being attacked by host complement. PLoS Negl Trop Dis 2011, 5(7):e1225.
• [21]Yang J, Gu Y, Yang Y, Wei J, Wang S, Cui S, Pan J, Li Q, Zhu X: Trichinella spiralis: immune response and protective immunity elicited by recombinant paramyosin formulated with different adjuvants. Exp Parasitol 2010, 124(4):403-408.
• [22]Zhao X, Hao Y, Yang J, Gu Y, Zhu X: Mapping of the complement C9 binding domain on Trichinella spiralis paramyosin. Parasit Vectors 2014, 7(1):80. BioMed Central Full Text
• [23]Dennis DT, Despommier DD, Davis N: Infectivity of the newborn larva of Trichinella spiralis in the rat. J Parasitol 1970, 56(5):974-977.
• [24]Yokoyama WM: Production of Monoclonal Antibodies. Current Protocols in Immunology 1995, 2-5.
• [25]Wang S, Zhu X, Yang Y, Yang J, Gu Y, Wei J, Hao R, Boireau P, Cui S: Molecular cloning and characterization of heat shock protein 70 from Trichinella spiralis. Acta Trop 2009, 110(1):46-51.
• [26]Wei J, Gu Y, Yang J, Yang Y, Wang S, Cui S, Zhu X: Identification and characterization of protective epitope of Trichinella spiralis paramyosin. Vaccine 2011, 29(17):3162-3168.
• [27]Iankov ID, Penheiter AR, Carlson SK, Galanis E: Development of monoclonal antibody-based immunoassays for detection of Helicobacter pylori neutrophil-activating protein. J Immunol Methods 2012, 384(1–2):1-9.
• [28]Maleki LA, Majidi J, Baradaran B, Abdolalizadeh J, Akbari AM: Production and characterization of murine monoclonal antibody against synthetic peptide of CD34. Hum Antibodies 2013, 22(1):1-8.
• [29]Kajiura S, Yashiki T, Funaoka H, Ohkaru Y, Nishikura K, Kanda T, Ajioka Y, Igarashi M, Hatakeyama K, Fujii H: Establishment and characterization of monoclonal and polyclonal antibodies against human intestinal fatty acid-binding protein (I-FABP) using synthetic regional peptides and recombinant I-FABP. J Immunoassay Immunochem 2008, 29(1):19-41.
• [30]Tanaka T, Slamon DJ, Cline MJ: Efficient generation of antibodies to oncoproteins by using synthetic peptide antigens. Proc Natl Acad Sci U S A 1985, 82(10):3400-3404.